Download PDF
Dtsch Med Wochenschr 2018; 143(02): 101-109
DOI: 10.1055/s-0043-106565
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Nierenmanifestationen bei Amyloidose und Sarkoidose

Renal involvement in amyloidosis and sarcoidosis
Jörg Beimler
,
Martin Zeier
Further Information

Publication History

Publication Date:
22 January 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Amyloidosis is a rare disease characterized by extracellular deposition of fibrils. Among the most common forms of systemic amyloidosis with renal involvement are AL-amyloidosis based on plasma cell dyscrasia and AA-amyloidosis in chronic inflammatory diseases. Depending on the affected renal compartment, the clinical appearance of renal amyloidosis varies. The pattern of renal amyloid deposition can be glomerular, interstitial, tubular or even vascular. Renal amyloid deposits are detected by renal biopsy. Patients with glomerular deposits typically show severe nephrotic syndrome with volume overload. Patients with predominantly tubulo-interstitial or vascular deposits typically exhibit lower proteinuria and progressive renal impairment. Treatment strategies for renal amyloidosis are primarily based on the treatment of the underlying disease including chemotherapy or stem cell transplantation in AL-amyloidosis or treatment of chronic inflammatory diseases in AA-amyloidosis. Granulomatous interstitial nephritis is the most common renal lesion occurring in sarcoidosis. Therapy of granulomatous interstitial nephritis is mainly based on the use of glucocorticoids.

Amyloidose und Sarkoidose sind seltene Systemerkrankungen, die mit unterschiedlichen renalen Manifestationen einhergehen können. Im Fall der systemischen Amyloidose besteht zudem das Risiko schwerwiegender bis tödlicher Komplikationen. Die Therapie der renalen Amyloidose-Manifestation befasst sich mit der Grunderkrankung und beinhaltet bei AL-Amyloidose Chemotherapie oder Stammzelltransplantation; bei der Sarkoidose sind Glukokortikoide wirksam

Schlüsselwörter

AL-Amyloidose - AA-Amyloidose - hereditäre Amyloidose - Sarkoidose

Key words

AL amyloidosis - AA amyloidosis - hereditary amyloidosis - sarcoidosis
 

  • Literatur

  • 1 Sipe JD, Benson MD, Buxbaum JN. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23: 209
    CrossrefPubMedGoogle Scholar
  • 2 Gertz MA, Comenzo R, Falk RH. et al. Definition of organ involvement and treatment response in immunoglobulin chain amyloidosis (AL). Am J Hematol 2005; 79: 319
    CrossrefPubMedGoogle Scholar
  • 3 Palladini G, Dispenzieri A, Gertz MA. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541
    CrossrefPubMedGoogle Scholar
  • 4 Leung N, Glavey SV, Kumar S. et al. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologia 2013; 98: 988
    PubMedGoogle Scholar
  • 5 Palladini G, Hegenbart U, Milani P. et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124: 2325
    CrossrefPubMedGoogle Scholar
  • 6 Pinney JH, Smith CJ, Taube JB. et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013; 161: 525-532
    CrossrefPubMedGoogle Scholar
  • 7 Lachmann HJ, Goodman HJ, Gilbertson JA. et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361
    CrossrefPubMedGoogle Scholar
  • 8 Blank N, Hegenbart U, Lohse P. et al. Risk factors for AA amyloidosis in Germany. Amyloid 2015; 22: 1
    CrossrefPubMedGoogle Scholar
  • 9 Zemer D, Pras M, Sohar E. et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001
    CrossrefPubMedGoogle Scholar
  • 10 Okuda Y, Ohnishi M, Matoba K. et al. Comparison of the clinical utility of Toculizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic disease. Mod Rheumatol 2014; 24: 137
    CrossrefPubMedGoogle Scholar
  • 11 Gillmore JD, Lovat LB, Persey MR. et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24
    CrossrefPubMedGoogle Scholar
  • 12 Bergesio F, Ciciani AM, Manganaro M. et al. Renal involvement in systemic amyloidosis: an Italian collaborative Study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941
    PubMedGoogle Scholar
  • 13 Nasr SH, Dogan A, Larsen CP. Leukocyte cell–derived chemotaxin 2–associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. CJASN 2015; 10: 2084-2093
    CrossrefPubMedGoogle Scholar
  • 14 Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis and therapeutics. JAMA 2011; 305: 391-399
    CrossrefPubMedGoogle Scholar
  • 15 Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologists perspective. Am J Kidney Dis 2006; 48: 856-870
    CrossrefPubMedGoogle Scholar
  • 16 Mahevas M, Lescure FX, Boffa JJ. et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine 2009; 88: 98-106
    CrossrefPubMedGoogle Scholar
  • 17 Rajakariar R, Sharples EJ, Raftery MJ. et al. Sarcoid tubulo-interstitial nephritis: long-term outcome and response to corticosteroid therapy. Kidney Int 2006; 70: 165-169
    CrossrefPubMedGoogle Scholar